TY - JOUR
T1 - Large prospective study of ramipril in patients with hypertension
AU - Kaplan, Norman M
AU - Sproul, L. E.
AU - Mulcahy, W. S.
PY - 1993/11/23
Y1 - 1993/11/23
N2 - The results of controlled trials demonstrate that ramipril lowers blood pressure in hypertensive patients, has a long duration of action suitable for once-daily administration in most patients, and is well tolerated. To assess the efficacy and safety of ramipril in a large cross-section of patients, we conducted a multicenter, open-label, prospective study, in which 591 men or women with essential hypertension (diastolic blood pressure ≥ 95 and ≤ 114 mmHg) received ramipril on a regimen of 1.25 to 10 mg once daily for 8 weeks. Forty-one percent of the patients required 2.5 mg and 81% required ≤ 5 mg once daily at study completion. Compared with baseline, ramipril reduced mean systolic/diastolic blood pressure by 19.9/14.7 mmHg (P < 0.001/P < 0.001). Ramipril reduced diastolic blood pressure to ≤ 90 mmHg or by at least 10 mmHg in 84.1% of the patients. Response rates were similar regardless of age, gender, and race. No patient stopped ramipril because of an adverse event or experienced an unexpected adverse event. In our real-world study, low-dose ramipril given once daily controlled blood pressure in most patients and was well tolerated.
AB - The results of controlled trials demonstrate that ramipril lowers blood pressure in hypertensive patients, has a long duration of action suitable for once-daily administration in most patients, and is well tolerated. To assess the efficacy and safety of ramipril in a large cross-section of patients, we conducted a multicenter, open-label, prospective study, in which 591 men or women with essential hypertension (diastolic blood pressure ≥ 95 and ≤ 114 mmHg) received ramipril on a regimen of 1.25 to 10 mg once daily for 8 weeks. Forty-one percent of the patients required 2.5 mg and 81% required ≤ 5 mg once daily at study completion. Compared with baseline, ramipril reduced mean systolic/diastolic blood pressure by 19.9/14.7 mmHg (P < 0.001/P < 0.001). Ramipril reduced diastolic blood pressure to ≤ 90 mmHg or by at least 10 mmHg in 84.1% of the patients. Response rates were similar regardless of age, gender, and race. No patient stopped ramipril because of an adverse event or experienced an unexpected adverse event. In our real-world study, low-dose ramipril given once daily controlled blood pressure in most patients and was well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=0027421914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027421914&partnerID=8YFLogxK
M3 - Article
C2 - 8269447
AN - SCOPUS:0027421914
SN - 0149-2918
VL - 15
SP - 810
EP - 818
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 5
ER -